
Ekaterina Poliakova-georgan
Examiner (ID: 12423)
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1637, 1635, 1674 |
| Total Applications | 898 |
| Issued Applications | 492 |
| Pending Applications | 151 |
| Abandoned Applications | 285 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19172815
[patent_doc_number] => 20240158789
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => NUCLEIC ACIDS SIMULTANEOUSLY INHIBITING EXPRESSION OF C-MET GENE AND PD-L1 GENE
[patent_app_type] => utility
[patent_app_number] => 18/281539
[patent_app_country] => US
[patent_app_date] => 2022-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6188
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18281539
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/281539 | NUCLEIC ACIDS SIMULTANEOUSLY INHIBITING EXPRESSION OF C-MET GENE AND PD-L1 GENE | Mar 10, 2022 | Pending |
Array
(
[id] => 19181211
[patent_doc_number] => 11987794
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-21
[patent_title] => Products and compositions
[patent_app_type] => utility
[patent_app_number] => 17/688789
[patent_app_country] => US
[patent_app_date] => 2022-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 33
[patent_no_of_words] => 26503
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 205
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688789
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/688789 | Products and compositions | Mar 6, 2022 | Issued |
Array
(
[id] => 17836390
[patent_doc_number] => 20220273695
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => MCM FOR GENE THERAPY TO ACTIVATE WNT PATHWAY
[patent_app_type] => utility
[patent_app_number] => 17/683699
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17683699
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/683699 | MCM FOR GENE THERAPY TO ACTIVATE WNT PATHWAY | Feb 28, 2022 | Abandoned |
Array
(
[id] => 19738503
[patent_doc_number] => 12215322
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-04
[patent_title] => Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/680940
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37221
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680940
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680940 | Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors | Feb 24, 2022 | Issued |
Array
(
[id] => 18972280
[patent_doc_number] => 20240052372
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => ALLELE-SPECIFIC GENOME EDITING OF THE NR2E3 MUTATION G56R
[patent_app_type] => utility
[patent_app_number] => 18/278494
[patent_app_country] => US
[patent_app_date] => 2022-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18278494
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/278494 | ALLELE-SPECIFIC GENOME EDITING OF THE NR2E3 MUTATION G56R | Feb 23, 2022 | Pending |
Array
(
[id] => 19232254
[patent_doc_number] => 20240189446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 18/263793
[patent_app_country] => US
[patent_app_date] => 2022-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60808
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263793
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/263793 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | Feb 22, 2022 | Pending |
Array
(
[id] => 19142517
[patent_doc_number] => 20240141359
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => GENOME EDITING FOR TREATING MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 18/278338
[patent_app_country] => US
[patent_app_date] => 2022-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14400
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18278338
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/278338 | GENOME EDITING FOR TREATING MUSCULAR DYSTROPHY | Feb 22, 2022 | Pending |
Array
(
[id] => 19172451
[patent_doc_number] => 20240158425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => MODIFIED ADENINES
[patent_app_type] => utility
[patent_app_number] => 18/277474
[patent_app_country] => US
[patent_app_date] => 2022-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11877
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18277474
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/277474 | MODIFIED ADENINES | Feb 20, 2022 | Pending |
Array
(
[id] => 17897421
[patent_doc_number] => 20220307083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT
[patent_app_type] => utility
[patent_app_number] => 17/670937
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670937
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/670937 | ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT | Feb 13, 2022 | Abandoned |
Array
(
[id] => 19096507
[patent_doc_number] => 20240115734
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY
[patent_app_type] => utility
[patent_app_number] => 18/264919
[patent_app_country] => US
[patent_app_date] => 2022-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33704
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -203
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264919
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/264919 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Feb 8, 2022 | Pending |
Array
(
[id] => 17930220
[patent_doc_number] => 20220325345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => Methods and Compositions for Assessing Patients with Preeclampsia-Related Conditions Using MicroRNA
[patent_app_type] => utility
[patent_app_number] => 17/592818
[patent_app_country] => US
[patent_app_date] => 2022-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12034
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592818
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/592818 | Methods and compositions for assessing patients with preeclampsia-related conditions using MicroRNA | Feb 3, 2022 | Issued |
Array
(
[id] => 19656888
[patent_doc_number] => 20240423953
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => METHODS AND COMPOSITIONS FOR TARGETING SV2 PROTEINS FOR IMMUNE REGULATION
[patent_app_type] => utility
[patent_app_number] => 18/262890
[patent_app_country] => US
[patent_app_date] => 2022-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -72
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18262890
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/262890 | METHODS AND COMPOSITIONS FOR TARGETING SV2 PROTEINS FOR IMMUNE REGULATION | Jan 24, 2022 | Pending |
Array
(
[id] => 19081933
[patent_doc_number] => 20240108734
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-04
[patent_title] => METHODS FOR TREATING AND AMELIORATING CANCER
[patent_app_type] => utility
[patent_app_number] => 18/273716
[patent_app_country] => US
[patent_app_date] => 2022-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40129
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273716
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/273716 | METHODS FOR TREATING AND AMELIORATING CANCER | Jan 20, 2022 | Pending |
Array
(
[id] => 18065691
[patent_doc_number] => 20220396778
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => Novel RNA Composition and Production Method for Use in iPS Cell Generation
[patent_app_type] => utility
[patent_app_number] => 17/648340
[patent_app_country] => US
[patent_app_date] => 2022-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17648340
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/648340 | Novel RNA Composition and Production Method for Use in iPS Cell Generation | Jan 18, 2022 | Abandoned |
Array
(
[id] => 19491794
[patent_doc_number] => 12110491
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-08
[patent_title] => Selective reduction of allelic variants
[patent_app_type] => utility
[patent_app_number] => 17/577832
[patent_app_country] => US
[patent_app_date] => 2022-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 161
[patent_figures_cnt] => 161
[patent_no_of_words] => 41635
[patent_no_of_claims] => 50
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17577832
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/577832 | Selective reduction of allelic variants | Jan 17, 2022 | Issued |
Array
(
[id] => 19001999
[patent_doc_number] => 20240066070
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => METHODS FOR THE EX VIVO INDUCTION OF TISSUE REGENERATION IN MICROBIOPSIES
[patent_app_type] => utility
[patent_app_number] => 18/272044
[patent_app_country] => US
[patent_app_date] => 2022-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31941
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -83
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272044
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/272044 | METHODS FOR THE EX VIVO INDUCTION OF TISSUE REGENERATION IN MICROBIOPSIES | Jan 10, 2022 | Pending |
Array
(
[id] => 17749938
[patent_doc_number] => 20220228143
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => MICRORNAS FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION
[patent_app_type] => utility
[patent_app_number] => 17/570714
[patent_app_country] => US
[patent_app_date] => 2022-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11271
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570714
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/570714 | MicroRNAs for cardiac regeneration through induction of cardiac myocyte proliferation | Jan 6, 2022 | Issued |
Array
(
[id] => 18077773
[patent_doc_number] => 20220403385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 17/567252
[patent_app_country] => US
[patent_app_date] => 2022-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28556
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17567252
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/567252 | COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Jan 2, 2022 | Abandoned |
Array
(
[id] => 19051271
[patent_doc_number] => 20240093240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => GENE FUNCTION CONTROL BY NOVEL GUIDE NUCLEIC ACID MECHANISM
[patent_app_type] => utility
[patent_app_number] => 18/259831
[patent_app_country] => US
[patent_app_date] => 2021-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13687
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259831
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/259831 | GENE FUNCTION CONTROL BY NOVEL GUIDE NUCLEIC ACID MECHANISM | Dec 27, 2021 | Pending |
Array
(
[id] => 17673053
[patent_doc_number] => 20220186220
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => USE OF miR-18b FOR PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE DISEASE AND NEUROMUSCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/554285
[patent_app_country] => US
[patent_app_date] => 2021-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11152
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554285
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/554285 | Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease | Dec 16, 2021 | Issued |